ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Discovery on Target 2023 (DOT 2023) ½«ÓÚ9ÔÂ25-28ÈÕÔÚ²¨Ê¿¶Ù¾ÙÐС£
×÷Ϊһ³¡ÐÂÐÍÒ©Îï°ÐµãÓëÊÖÒÕµÄÒµ½çÊ¢»á£¬DOT 2023½«ÖصãÏÈÈÝÈÈÃż°ÐÂÐ˰еãÓëÊÖÒÕÏ£Íû£¬²¢Ì½ÌÖ´ÓÉúÎïÖÆ¼Áµ½Ð¡·Ö×ÓµÈÐÂÐÍÖÎÁÆÒ©ÎïµÄÑз¢Óë°ÐµãÑéÖ¤Õ½ÂÔ¡£DOT2023½«¾Û½¹ÃâÒßµ÷Àí¡¢ÂѰ×Öʽµ½â¼ÁºÍRNAµÈÈÈÃÅ»°Ì⣬ÅäºÏ̽ÌÖת¼Òò×Ó¡¢Ð¡·Ö×ÓÖ×ÁöÒ©¼°Æä°ÐµãºÍ¼¤Ã¸µÈÑо¿Æ«Ïò¡£
×ðÁú¿Ê±¹ú¼ÊÑз¢Ð§ÀͲ¿Ö´Ðи±×ܲô÷ѧ¶«²©Ê¿½«Ïòµ¼×ðÁú¿Ê±ÍŶӳöϯ±¾´Î¾Û»á£¬Õ¹Î»ºÅ£º#221¡£
ÆÚ´ýÓëÄúÔÚ²¨Ê¿¶ÙÏÖ³¡½»Á÷£¬ÎªÄúÌṩÖ×ÁöÒ©Îï·¢Ã÷ºÍ¿ª·¢¹ÜÏßÌṩ×ÛºÏЧÀÍ¡£
ÈÕÆÚ | 2023Äê9ÔÂ25-28ÈÕ
ËùÔÚ | ²¨Ê¿¶Ù£¬ÃÀ¹ú
×ðÁú¿Ê±Õ¹Î» | #221
´÷ѧ¶« ²©Ê¿ ×ðÁú¿Ê±¹ú¼ÊÑз¢Ð§ÀͲ¿Ö´Ðи±×ܲÃ
ÃÀ¹úÂéÊ¡Àí¹¤´óѧÓлú»¯Ñ§²©Ê¿£¬²©Ê¿ºó£¬Éî¸ûÓÚÖÐÊàÉñ¾ÏµÍ³¼²²¡¡¢Ñ¬È¾²¡ºÍÖ×Áö¼²²¡»¯Ñ§Ò©ÎïµÄÑз¢20ÓàÔØ£¬¶ÔÒ©Îï·¢Ã÷Àú³ÌÖаüÀ¨ÃçÍ·»¯ºÏÎï¼òÖ±¶¨¼°ÓÅ»¯£¬ÒÔ¼°ÀÖ³ÉÉú³¤µ½¸ßÖÊÁ¿µÄÁÙ´²ºòÑ¡»¯ºÏÎïÓÐ×ÅÉî¿ÌµÄÃ÷È·ºÍ¸»ºñµÄʵ¼ùÂÄÀú¡£´÷ѧ¶«²©Ê¿¼ÓÈëÖ÷³ÖÑз¢µÄÒ©ÎïÓÐÒÑÉÏÊÐÒ©ÎÈçHORIZANT?/REGNITE?£»ÁÙ´²Ò©ÎÈçJNJ-75276617£»ÁÙ´²ºòÑ¡»¯ºÏÎÈçARBACLOFEN PLACARBIL£¬XP21279£¬XP23829µÈ¡£
ÔÚ¼ÓÈë×ðÁú¿Ê±Ö®Ç°£¬´÷²©Ê¿ÔøÓÚÎ÷°²ÑîÉ¡¢»ÔÔ´ÉúÎï¿Æ¼¼¡¢GSK¡¢XenoportµÈº£ÄÚÍâ×ÅÃûÒ©Æó¼°CROµ£µ±¸ß¹Ü£¬ÓÐ×Å׿ԽµÄÏîÄ¿ÖÎÀí¼Í¼ºÍ¸»ºñµÄÖÎÀíÂÄÀú¡£
´Ë´Î´ó»á°²ÅÅÁ˸»ºñµÄ¶¨ÏòÖ÷ÌâÂÛ̳£¬×ðÁú¿Ê±¾«Ñ¡ÁËÖØµãÐÅÏ¢£¬¹©Äú²Î¿¼¡£
Emerging Immune Modulation Strategies
ÐÂÐËÃâÒßµ÷ÀíÕ½ÂÔ£ºÊ¶±ð¡¢ÏàʶºÍÕ¹ÍûÃâÒß·´Ó¦µÄ¼ì²âÒªÁìºÍÊÖÒÕ #Ò©Îï·¢Ã÷ #ÃâÒßÖÎÁÆ
Strategies for Targeting Kinases
°ÐÏò¼¤Ã¸µÄÕ½ÂÔ£ºÑо¿¡¢µ÷ÀíºÍ½µ½â¼¤Ã¸µÄÐÂÐÍ»¯Ñ§ÒªÁìºÍÊÖÒÕ #Ñ¡ÔñÐÔ°ÐÏò¼¤Ã¸
Protein Degraders and Molecular Glues Part-1
#PROTAC
ÂѰ×Öʽµ½â¼ÁºÍ·Ö×Ó½º-Part1£º¹²¼Û»¯Ñ§¡¢ÓÃÓÚÓÕµ¼¿¿½üµÄÐÂÐÍÅþÁ¬Ã¸
Proteomics-Driven Drug Discovery
#ÂѰ×ÖÊ×éѧ #Ò©Îï·¢Ã÷
ÂѰ×ÖÊ×éѧÇý¶¯µÄÒ©Îï·¢Ã÷£º»¯Ñ§ÂѰ×ÖÊ×éѧ¡¢»¯Ñ§ÉúÎïѧºÍ±íÐÍɸѡµÄÓÐÓÃʹÓÃ
Small Molecules Targeting RNA
#Á¢ÒìÒªÁì
°ÐÏòRNAµÄС·Ö×Ó£ºÈ·¶¨ÓÃÓÚÖÎÁƸÉÔ¤µÄÐÂÒ©ÎïģʽºÍRNA·Ö×Ó
Small Molecules for Cancer Targets-Part 1
#С·Ö×Ó»¯ºÏÎïÏ£Íû
ÓÃÓÚ°©Ö¢°ÐµãµÄС·Ö×Ó-Part1£º·¢Ã÷δÀ´µÄ¿Ú·þÉúÎï¿ÉÓÃÖ×ÁöÖÎÁÆÒ©Îï
Neurodegeneration Targets
#Éñ¾ÍËÐÐÐÔ¼²²¡ #°¢¶û´Äº£Ä¬ÊÏÖ¢ #ÅÁ½ðÉÊÏÖ¢ #ÁÙ´²¿ª·¢
Éñ¾±äÐ԰е㣺½¥½øÐÔÖÐÊàÉñ¾ÏµÍ³¼²²¡µÄÒ©ÎïÑз¢
GPCR-Based Drug Discovery
#ÃâÒßÖ×Áöѧ #°ÐÏòGPCR
»ùÓÚGPCRµÄÒ©ÎïÑз¢£ºÒÔGÂѰ׿ÁªÊÜÌåΪ°ÐµãѰÕÒеÄÖÎÁƼƻ®
Antibodies Against Membrane Protein Targets-Part 1
#ÂѰ×Öʹ¤³Ì
Õë¶ÔĤÂѰװеãµÄ¿¹Ìå-Part1£ºÌ½Ë÷ÏÂÒ»´úÊÖÒÕ
AI/ML-Enabled Drug Discovery-Part 1
#È˹¤ÖÇÄÜ #È·¶¨°ÐµãºÍϸ°ûͨ·
È˹¤ÖÇÄÜ/ML Çý¶¯µÄÒ©Îï·¢Ã÷-Part1£ºÊ¶±ðаеãºÍÐÂ;¾¶
Protein Degraders and Molecular Glues-Part 2
#ÐÂÐÍÂѰ×Öʽµ½â¼Á
ÂѰ×Öʽµ½â¼ÁºÍ·Ö×Ó½º-Part2£ºÐÂÐͽµ½â¼ÁģʽµÄÉè¼ÆÓëÓÅ»¯
Genomics-Driven Drug Discovery
#ÊÖÒÕÁªºÏ
»ùÒò×éѧÇý¶¯µÄÒ©Îï·¢Ã÷£ºÊ¹ÓÃCRISPRɸѡ¡¢µ¥Ï¸°û²âÐò¡¢¿Õ¼äת¼×éºÍºÏ³ÉÉúÎïѧ
Targeting Transcription Factors
#ת¼Òò×Ó
°ÐÏòת¼Òò×Ó£ºÌá¸ß³ÉÒ©ÐÔµÄÁ¢Ò컯ѧҪÁì¡¢¼ì²âÒªÁìºÍģʽ
Small Molecules for Cancer Targets-Part 2
#С·Ö×Ó»¯ºÏÎïÏ£Íû
ÓÃÓÚ°©Ö¢°ÐµãµÄС·Ö×Ó-Part2£º·¢Ã÷δÀ´µÄ¿Ú·þÉúÎï¿ÉÓÃÖ×ÁöÖÎÁÆÒ©Îï
Fibrosis and Inflammation
#ÏËά»¯»úÖÆ
ÏËά»¯ºÍÑ×Ö¢£ºNASH¡¢·ÎÏËά»¯¡¢Ñ×Ö¢ÐÔ³¦²¡ºÍ×ÔÉíÃâÒßµÄÒ©Îï·¢Ã÷
Lead Generation Strategies
#ÂѰ×ÖÊ-ÂѰ×ÖÊÏ໥×÷Óã¨PPI£© #ø´ß»¯
Ïȵ¼Ñз¢Õ½ÂÔ£ºÐ¡·Ö×ÓÒ©Îï·¢Ã÷Á¢Òì
Antibodies Against Membrane Protein Targets-Part 2
#ĤÂѰװеã
Õë¶ÔĤÂѰװеãµÄ¿¹Ìå-Part1£ºÕë¶ÔĤÂѰװеãµÄÉúÎïÖÎÁƹ¤³ÌÓ뿪·¢
AI/ML-Enabled Drug Discovery-Part2
#È˹¤ÖÇÄÜÓ¦Óà #Ò©ÎïÉè¼Æ #»¯ºÏÎïɸѡ #Ïȵ¼ÎïÅжÏÓëÓÅ»¯ #ÌØÕ÷Õ¹Íû
È˹¤ÖÇÄÜ/ML Çý¶¯µÄÒ©Îï·¢Ã÷-Part2£ºÈ˹¤ÖÇÄÜ/ML ÔÚÒ©ÎïÉè¼Æ¡¢É¸Ñ¡ºÍÏȵ¼ÎïÓÅ»¯ÖеÄÓ¦ÓÃ
¡ª¡ªEND¡ª¡ª
×ðÁú¿Ê±¹ú¼ÊÑз¢Ð§ÀͲ¿¼¯½áÁËÒ»Ö§ÍòÄÜÐÍÍŶӣ¬ÓµÓи»ºñµÄÍâÑóÁôѧÊÂÇéÅä¾°µÄÖÎÀíÍŶӺÍʵÑéÖ°Ô±¡£Í¬Ê±£¬Å䱸ÌìÏÂÏȽøË®Æ½µÄºÏ³ÉʵÑéÊÒ¡¢ÆÊÎöʵÑéÊÒ¡¢ºÍÅäÌ׵ĸ߶ËÒÇÆ÷×°±¸£¬ÈçASAP MASS¡¢ÊÖÌ×Ïä¡¢¶àëĺϳÉÒÇ¡¢ÖÖÖֹ⻯ѧ·´Ó¦Æ÷¡¢µç»¯Ñ§·´Ó¦Æ÷£¬ÎªÒ©ÎïÑз¢ÊÂÇéÌṩÁËǿʢµÄÖ§³Ö¡£